Abstract
From experiments reported it is concluded that heparin combines with and inactivates Christman factor (C.F.) to form reversibly a heparin-C.F. complex. Apart from the effect of heparin on C.F. and on thrombin, heparin in moderate concentrations was not shown to inactivate any other coagulation factors.
“Available” heparin is defined as heparin in such a state that it can delay some clotting systems. Heparin was rendered “unavailable” or inactive by plasma C.F. and especially by serum C.F., by platelet protein (but not intact platelets), and by platelet-like activity of serum (P.L.A.S.). These three proteins uniquely among all the plasma and serum proteins inactivate heparin.
If an appropriate concentration of heparin is added to whole blood the clotting time is prolonged, due presumably to the inactivation of C.F. by heparin: “available” heparin disappears during clotting and none is found in the serum. The interactions summarized above probably account for these findings. The disappearance of available heparin would also account for the normal thrombin generation and prothrombin consumption observed when heparinized blood clots.
Some properties of P.L.A.S. are reported and its possible role in normal coagulation is considered. Heparin is known to become attached preferentially to one protein rather than another. Some plasma and serum fractions can be arranged in order of their increasing affinity for heparin thus: β Lipoproteins<thrombin clotting system<C.F.<platelet protein<protamine sulphate.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BERGSAGEL D. E. The role of calcium in the activation of the Christmas factor. Br J Haematol. 1955 Apr;1(2):199–212. doi: 10.1111/j.1365-2141.1955.tb05501.x. [DOI] [PubMed] [Google Scholar]
- BERNFELD P., DONAHUE V. M., BERKOWITZ M. E. Interaction of human serum beta-lipoglobulin with polyanions. J Biol Chem. 1957 May;226(1):51–64. [PubMed] [Google Scholar]
- BIGGS R., DOUGLAS A. S., MACFARLANE R. G. The action of thromboplastic substances. J Physiol. 1953 Dec 29;122(3):554–569. doi: 10.1113/jphysiol.1953.sp005020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- BIGGS R., DOUGLAS A. S. The thromboplastin generation test. J Clin Pathol. 1953 Feb;6(1):23–29. doi: 10.1136/jcp.6.1.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
- DOUGLAS A. S. The action of heparin in the prevention of prothrombin conversion. J Clin Invest. 1956 May;35(5):533–536. doi: 10.1172/JCI103306. [DOI] [PMC free article] [PubMed] [Google Scholar]
- GARRETT J. V., KLEIN E. Differentiation of antiheparin and thromboplastin-generating factors in human platelets. Proc Soc Exp Biol Med. 1957 Dec;96(3):823–825. doi: 10.3181/00379727-96-23620. [DOI] [PubMed] [Google Scholar]
- HOUGIE C. Anticoagulant action of protamine sulphate. Proc Soc Exp Biol Med. 1958 May;98(1):130–133. doi: 10.3181/00379727-98-23963. [DOI] [PubMed] [Google Scholar]
- McGOVERN V. J. Reactions to injury of vascular endothelium with special reference to the problem of thrombosis. J Pathol Bacteriol. 1955 Jan-Apr;69(1-2):283–293. doi: 10.1002/path.1700690136. [DOI] [PubMed] [Google Scholar]
- O'BRIEN J. R. The platelet-like activity of serum. Br J Haematol. 1955 Apr;1(2):223–228. [PubMed] [Google Scholar]
- RAPAPORT S. I., AMES S. B. Anti-heparin activity of erythrocyte hemolysate. Proc Soc Exp Biol Med. 1957 May;95(1):158–160. doi: 10.3181/00379727-95-23152. [DOI] [PubMed] [Google Scholar]
- SHANBERGE J. N., BARLAS A., REGAN E. E. The effect of protamine on thromboplastin generation. J Lab Clin Med. 1958 Nov;52(5):744–753. [PubMed] [Google Scholar]
- SNELLMAN O., SYLVEN B., JULEN C. Analysis of the native heparin-lipoprotein complex including the identification of a heparin complement (heparin co-factor) obtained from extracts of tissue mast cells. Biochim Biophys Acta. 1951 May;7(1):98–109. doi: 10.1016/0006-3002(51)90008-x. [DOI] [PubMed] [Google Scholar]
- WALTON K. W. Chemistry and mode of action of heparin and related compounds. Br Med Bull. 1955;11(1):62–69. doi: 10.1093/oxfordjournals.bmb.a069449. [DOI] [PubMed] [Google Scholar]
- WOLF P. Lipid extracts of platelets and brain as substitutes for platelets in coagulation tests. Br J Haematol. 1956 Oct;2(4):375–385. doi: 10.1111/j.1365-2141.1956.tb06712.x. [DOI] [PubMed] [Google Scholar]
- van CREVOLD S., PAULSSEN M. M. P. Significance of clotting factors in blood-platelets, in normal and pathological conditions. Lancet. 1951 Aug 11;2(6676):242–244. [PubMed] [Google Scholar]